OBJECTIVES: To compare the cost of treatment of selected cancers with patented drugs: India versus neighboring countries. METHODS: Patented anticancer drugs (expiring in/after 2016) were selected using USFDA Orange-Book. These drugs were further, screened at the Indian national regulatory database for their marketing approval status in the country. The price of these drugs was calculated using CIMS – India online. Indication and dose as approved by USFDA for CML and Advance Breast Cancer were considered to estimate the cost of therapy. The STGs recommended by cancer.org were used. RESULTS: Twelve patented anticancer drugs are approved for marketing in India. Of these, we note that 4 are not available in the Indian market (Crizotinib, Ruxolitinib, Degarelix & Vemurafenib); and, the patent of 3 has been challenged (Sorafenib, Dasatinib & Fulvestrant). Lapatinib is approved for treatment of CML while Nilotinib, Ixabepilone & Eribulin are for different stages of Breast Cancer. The cost of treatment of CML using Lapatinib is $8000/year in India; and, this is $18000, $17000, $17000 & $7000 for Philippines, Malaysia, Pakistan & Indonesia, respectively. Likewise, the cost of treatment of Advanced Breast Cancer using Nilotinib is $3000/year in India while $67000, $54000, $38000 & $4000 for Malaysia, Pakistan, Indonesia & Philippines, respectively. The costs are rounded. Though it is not meaningful to compare these costs with American costs; CML treatment costs $51000/year while for Advance Breast Cancer treatment costs $1,20,000/year. CONCLUSIONS: In India, the cost of treatment of CML is approximately half when compared to most of the neighboring countries. For Advanced Breast Cancer, the costs are 12-22 times lower on similar comparison.